Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer
| Autor: | Hendrika Boezen, de Rudolf Boer, Johan Lefrandt, van den Maarten Berg, Yoran M. Hummel, Adriaan A. Voors, Richard van Altena, Janine Nuver, de Elisabeth G. E. Vries, Jourik A. Gietema, Andries J. Smit |
|---|---|
| Přispěvatelé: | Damage and Repair in Cancer Development and Cancer Treatment (DARE), Life Course Epidemiology (LCE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Cardiovascular Centre (CVC), Groningen Kidney Center (GKC), Groningen Research Institute for Asthma and COPD (GRIAC), Vascular Ageing Programme (VAP) |
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male Cardiac function curve cardiovascular damage medicine.medical_specialty Heart Diseases medicine.drug_class Galectin 3 VENTRICULAR DIASTOLIC FUNCTION Diastole Bleomycin Ventricular Dysfunction Left Young Adult Testicular Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols Natriuretic Peptide Brain medicine Natriuretic peptide Humans Longitudinal Studies Young adult Testicular cancer METABOLIC SYNDROME Etoposide GALECTIN-3 VEIN ENDOTHELIAL-CELLS Ejection fraction business.industry LONG-TERM SURVIVORS IN-VITRO Hematology Middle Aged medicine.disease Chemotherapy regimen testicular cancer Oncology CARDIOVASCULAR-DISEASE Echocardiography Heart failure Disease Progression Cardiology HEART-FAILURE Cisplatin business MITRAL ANNULUS VELOCITY |
| Zdroj: | Annals of Oncology, 22(10), 2286-2293. Oxford University Press |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/mdr408 |
| Popis: | Background: Cross-sectional studies showed that treatment with cisplatin chemotherapy for testicular cancer is associated with an increased incidence of cardiac dysfunction. We investigated longitudinal progression of and contributing factors to cardiac dysfunction in testicular cancer survivors.Patients and methods: Cardiac assessments were carried out before 10 months (range 7-15 months) and 6.9 years (range 4.9-9.7 years) after start of cisplatin-based chemotherapy, consisting of echocardiography [systolic function (left ventricular ejection fraction, LVEF), diastolic function (myocardial tissue velocities; tissue velocity imaging of early diastole, TVI Et)] and plasma biomarkers (N-Terminal pro brain natriuretic peptide, NT-proBNP; galectin-3).Results: In 37 patients [median age 34 years (range 24-51 years)], the incidence of abnormal TVI Et increased from 0% at baseline and 4.5% at 10 months (in 27 patients) to 16.7% at 6.9 years post-chemotherapy (P = 0.03). One patient developed LVEF Conclusions: In this longitudinal cohort study, we observed a gradual decline in diastolic parameters after cisplatin-based chemotherapy for testicular cancer, whereas the rate of systolic dysfunction remains low. The association of larger declines in diastolic parameters with hypertension and obesity stresses the need to monitor and treat cardiovascular risk factors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|